Regression of prostatic hypertrophy by osaterone acetate in dogs.

Abstract

The prostatic regression effect of oral administration of a new steroidal anti-androgen, osaterone acetate, was investigated in dogs with prostatic hypertrophy. To dogs with prostatic hypertrophy, 0.1-1.0 mg/kg of osaterone acetate was orally administered for one week, and the regression rate was observed. It was shown that administration of osaterone acetate at 0.2 mg/kg or higher, sharply regressed prostatic hypertrophy during the early stage. Therefore, this agent may be clinically applicable as a therapeutic agent for benign prostatic hypertrophy.

• Authors: T Tsutsu, T Hori, M Shimizu, H Orima, E Kawakami, S Fukuda
• Journal: The Journal of veterinary medical science (J Vet Med Sci) Vol. 62 Issue 10 Pg. 1115-9 (Oct 2000) ISSN: 0916-7250 [Print] Japan
• PMID: 11073087 (Publication Type: Journal Article)

Chemical References

• Androgen Antagonists
• Chlormadinone Acetate
• Testosterone
• Luteinizing Hormone
• osaterone acetate

Topics

• Administration, Oral
• Androgen Antagonists (administration & dosage, blood, therapeutic use)
• Animals
• Chlormadinone Acetate (administration & dosage, analogs & derivatives, blood, therapeutic use)
• Dog Diseases (blood, drug therapy)
• Dogs
• Luteinizing Hormone (blood)
• Male
• Prostatic Hyperplasia (drug therapy, veterinary)
• Testosterone (blood)